Company news

bioAffinity Technologies, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test

October 8, 2024

bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales

August 13, 2024

bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

August 1, 2024

bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath® Lung

July 8, 2024

bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests

June 11, 2024

bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes

May 14, 2024

bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results

March 31, 2024

bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement

March 5, 2024

bioAffinity Technologies Reports Accelerating Sales Growth of CyPath® Lung

March 4, 2024

bioAffinity Technologies Announces Award of Therapeutic Patent for Treatment of Cancer

January 22, 2024

bioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors

December 4, 2023

bioAffinity Technologies Reports Third Quarter 2023 Financial Results and Provides Business Update

November 13, 2023

bioAffinity Technologies Names Dallas J. Coleman as National Director of Sales

November 5, 2023

bioAffinity Technologies Acquires Laboratory Assets of Precision Pathology Services

September 18, 2023

bioAffinity Technologies Reports Second Quarter 2023 Financial Results and Provides Business Update

August 13, 2023

bioAffinity Technologies Reports First Quarter 2023 Financial Results

May 14, 2023

bioAffinity Technologies Names Michael Dougherty as Chief Financial Officer

April 30, 2023

bioAffinity Technologies to Ring Nasdaq Closing Bell Today

April 4, 2023

bioAffinity Technologies Reports Fourth Quarter and Full Year 2022 Financial Results

March 30, 2023

bioAffinity Technologies Announces Publication of Peer-Reviewed Paper on Proprietary Beads Used in CyPath® Lung for Noninvasive Detection of Early-Stage Lung Cancer

March 27, 2023

bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023

March 23, 2023

bioAffinity Technologies Appoints Julie Anne Overton Director of Corporate Communications

February 12, 2023

bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research

January 23, 2023

bioAffinity Technologies Announces Notice to Award U.S. Patent Protecting Novel Compounds for Specific Delivery of Cancer Treatments

January 3, 2023

bioAffinity Technologies Expands Diagnostic Division with Promotions and New Hires to Strengthen Clinical Bench

December 14, 2022

bioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting

November 30, 2022

bioAffinity Technologies Reports Third Quarter 2022 Financial Results and Provides Business Update

November 13, 2022

bioAffinity Technologies Announces Sheila Habib, MD and David Hill, MD Join the Company’s Scientific and Medical Advisory Board

November 9, 2022

bioAffinity Technologies to Report Third Quarter 2022 Financial Results

November 7, 2022

bioAffinity Technologies Announces Award of Therapeutic Patents in China, Mexico and Australia

October 24, 2022

bioAffinity Technologies Receives Additional $7.7M from Exercise of Warrants, Total Capital from Public Offering Increases to Approximately $15.6M

September 27, 2022

bioAffinity Technologies, Inc. Announces Closing of $7.8 Million Initial Public Offering

September 5, 2022

bioAffinity Technologies Announces Pricing of IPO

August 31, 2022

← Newer news releases

Calls

Decks

The 5 newest of 6 decks. Every deck is listed under its year.